Price$0.32-0.01 (-3.63%)
01:30 PM07:45 PM
News · 26 weeks64-31%
2025-12-072026-05-31
Mix2690d
- SEC Filings19(73%)
- Other4(15%)
- Insider2(8%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form DEF 14A filed by Profusa Inc.DEF 14A - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 424B3 filed by Profusa Inc.424B3 - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Other Events8-K - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 10-Q filed by Profusa Inc.10-Q - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- PRProfusa Announces Listing Transfer to The Nasdaq Capital MarketBERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market. The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier. About ProfusaBased in Berkeley, CA, Profusa is a commercial stage digital health co
- PRFormer Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of DirectorsWEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense platform spanning drone warfare, counter-UAS, demining, and command-and-control applications, today announced the appointment of Peter M. O'Rourke Sr. as an independent member of its Board of Directors, effective immediately. Mr. O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs (VA) under the Trump administration in 2018, where he led over 380,000 employees and helped oversee one of the largest federal healthcare and benefits systems in the country, with an annual bu
- SECSEC Form PRE 14A filed by Profusa Inc.PRE 14A - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- PRProfusa Receives Favorable Nasdaq Listing DeterminationBERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company's request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company's continued listing on Nasdaq is subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with the bid price and stockholders' equity requirements for continued listing on the
- INSIDERSEC Form 4 filed by Director Stover Jack E4 - Profusa, Inc. (0001859807) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Knechtel Fred S.4 - Profusa, Inc. (0001859807) (Issuer)
- PRProfusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder ValueCompany focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Directors has initiated a Board-led process to evaluate strategic alternatives intended to maximize shareholder value and support the Company's highest-priority commercial, regulatory and platform-e
- SECSEC Form EFFECT filed by Profusa Inc.EFFECT - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 424B3 filed by Profusa Inc.424B3 - Profusa, Inc. (0001859807) (Filer)
- SECAmendment: SEC Form S-1/A filed by Profusa Inc.S-1/A - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form S-1 filed by Profusa Inc.S-1 - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- SECSEC Form 10-K filed by Profusa Inc.10-K - Profusa, Inc. (0001859807) (Filer)
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
- PRProfusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics PlatformCompany secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics™ multi-omics diagnostics platform from BioInsights LLC ("BioInsights"). The Company believes this acquisition, a
- SECProfusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Profusa, Inc. (0001859807) (Filer)
PFSA FAQ
4 questionsWhere does PFSA stock trade?
Profusa Inc. (PFSA) is listed on NASDAQ.What sector and industry is PFSA in?
Profusa Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to PFSA?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PFSA side-by-side with any of them on Quantisnow.How can I track PFSA on Quantisnow?
Quantisnow aggregates Profusa Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PFSA to receive live email and push alerts on every new disclosure.